Assessing QT prolongation and electrocardiography restitution using a beat-to-beat method

Cardiology Journal

Volumn 17, Issue 3, 2010, Pages 230-243

  Fossa, Anthony A ^a   Zhou, Meijian ^a  

^a ICardiac Technologies   (United States)

Author keywords

Autonomic tone; Beat to beat; Electrocardiogram; Qt prolongation; Restitution

Indexed keywords

ALGORITHM; ARRHYTHMOGENESIS; AUTONOMIC INNERVATION; BOOTSTRAPPING; CARDIOVASCULAR PARAMETERS; ELECTROCARDIOGRAPHY RESTITUTION; FALSE POSITIVE RESULT; HEART STRESS; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYSTERESIS; QT INTERVAL; QT PROLONGATION; REVIEW; RR INTERVAL; SIGNAL PROCESSING; TORSADE DES POINTES; ARRHYTHMIAS, CARDIAC; AUTONOMIC NERVOUS SYSTEM; ELECTROCARDIOGRAPHY; HEART MUSCLE CONDUCTION SYSTEM; HEART RATE; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROGNOSIS; REPRODUCIBILITY; TIME;

ARRHYTHMIAS, CARDIAC; AUTONOMIC NERVOUS SYSTEM; ELECTROCARDIOGRAPHY; HEART CONDUCTION SYSTEM; HEART RATE; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SIGNAL PROCESSING, COMPUTER-ASSISTED; TIME FACTORS;

EID: 77953342223     PISSN: 18975593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart, 1920; 7: 353-370.
2. Fridericia LS. EKG systolic duration in normal subjects and heart disease patients. Acta Med Scand, 1920; 53: 469-488.
3. Malik M. Problems of heart rate correction is assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol, 2001; 12: 411-420.
4. Pratt CM, Ruberg S, Morgenroth J et al. Dose-response relationship between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: Distinguishing a drug effect from spontaneous variability. Am Heart J, 1996; 131: 472-480.
5. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA, 1993; 269: 1513-1518.
6. Wysowski DK, Corken A, Gallo-Torres H, Talarico L, Rodriguez EM. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration Regulatory Actions. Am Coll Gastroenterol, 2001; 96: 1698-1703.
7. ICH Harmonized Tripartite Guideline E14. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for nonantiarrhythmic drugs 2005. (Available at http:////www.fda.gov/downloads/RegulatoryInformation/Guidances//UCM129357.pdf).
8. Scirica BM, Morrow DA, Hod H et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non-ST-segment elevation acute coronary syndrome. Results from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation, 2007; 116: 1647-1652.
9. Strom B, Faich G, Eng S et al. Comparative mortality associated with ziprasidone vs. olazapine in real-world use: The ziprasidone observational study of cardiac outcomes (ZODIAC) Schizophrenia Res, 2008; 98: 160-161.
10. Extramiana F, Maison-Blanche P, Cabanis M-J, Ortemann--Renon C, Beufils P, Leenhardt A. Clinical assessment of drug--induced QT prolongation in association with heart rate changes. Clin Pharmacol Ther, 2005; 77: 247-258.
11. Intunivä (guanfacine extended release) patient package insert information, August 2009 (Available at http://www.intuniv.com//documents/INTUNIV_Full_Prescribing_Information.pdf).
12. www.cardiac-safety.org.
13. Fossa AA, Wisialowski T, Magnano A et al. Dynamic beat-to--beat modeling of the QT-RR interval relationship: analysis of QT prolongation during alterations of autonomic state versus human ether a-go-go-related gene inhibition. J Pharmacol Exp Ther, 2005; 312: 1-11.
14. Koenker R, Ng P, Portnoy S. Quantile smoothing splines. Biometrika, 1994; 81: 673-680.
15. Viskin S, Postema PG, Bhuiyan ZA et al. The response of the QT interval to the brief tachycardia provoked by standing. A bedside test for diagnosing Long QT Syndrome. J Am Coll Cardiol, 2010; 55: 1955-1961.
16. Efron B. Bootstrap methods: Another look at the jackknife. Ann Statist, 1979; 7: 1-26.
17. Berger RD, Kasper EK, Baughman KL, Marban E, Calkins H, Tomaselli GF. Beat-to-beat QT variability. Novel evidence for repolarization lability in ischemic and nonischemic dilated cardiomyopathy. Circulation, 1997; 96: 1557-1565.
18. Satomi K, Shimizu W, Takaki H et al. Response of beat-by-beat QT variability to sympathetic stimulation in the LQT1 form of congenital long QT syndrome. Heart Rhythm, 2005; 2: 149-154.
19. Oosterhoff P, Oros A, Vos MA. Beat-to-beat variability of repolarization: A new parameter to determine arrhythmic risk of an individual or identify proarrhythmic drugs. Anadolu Kardiyol Derg, 2007; 7: 73-78.
20. Fossa AA, Wisialowski T, Crimin K. QT prolongation modifies dynamic restitution and hysteresis of the beat-to-beat QT-TQ interval relationship during normal sinus rhythm under varying states of delayed repolarization. J Pharmacol Exp Ther, 2006; 316: 498-506.
21. Fossa AA, Wisialowski T, Crimin K et al. Analyses of dynamic beat-to-beat QT-TQ (ECG restitution) changes in humans under normal sinus rhythm and prior to an event of torsades de pointes during QT prolongation caused by sotalol. ANE, 2007; 12: 338-348.
22. Weiss JN, Garfinkel A, Karagueuzian HS, Qu Z, Chen P-S. Chaos and the transition to ventricular fibrillation. A new approach to antiarrhythmic drug evaluation. Circulation, 1999; 99: 2819-2826.
23. Riccio ML, Koller ML, Gilmour RF Jr. Electrical restitution and spatiotemporal organization during ventricular fibrillation. Circ Res, 1999; 84: 955-963.
24. Nash MP, Bradley CP, Sutton PM et al. Whole heart action potential duration restitution properties in cardiac patients: A combined clinical and modeling study. Exp Physiol, 2006; 91: 339-354.
25. Graboys TB, Lown B, Podrid PJ, DeSilva R. Long-term survival of patients with malignant ventricular arrhythmia treated with antiarrhythmic drugs. Am J Cardiol, 1982; 50: 437-443.
26. Bigger JT Jr, Fleiss JL, Kleiger R, Miller JP, Rolnitsky LM. The relationship among ventricular arrhythmias, left ventricular dysfunction and mortality in the 2 years after myocardial infarction. Circulation, 1984; 69: 250-258.
27. Karma A. Electrical alternans and spiral wave break-up in cardiac tissue. Chaos, 1994; 4: 461-472.
28. Karagueuzian HS, Chen P-S. Graded response and restitution hypotheses of ventricular vulnerability to fibrillation: Insights into the mechanism of initiation of fibrillation. J Electrocardiol, 1999; 32: S87-S91.
29. Handzel R, Garnett C, Li M et al. Comparison of highly-automatic versus FDA-submitted QT measurements for the detection of moxifloxacin induced prolongation of the QTc interval. Computers Cardiol, 2008; 35: 693-696.
30. Vaglio M, Couderc J-P, McNitt S, Xia X, Moss AJ, Zareba W. A quantitative assessment of T-wave morphology in LQT1, LQT2, and healthy individuals based on Holter recording technology. Heart Rhythm, 2008; 5: 11-18.
31. Badilini F, Fayn J, Maison-Blanche P et al. Quantitative aspects of ventricular repolarization: relationship between three-dimensional T wave loop morphology and scalar QT dispersion. ANE, 1997; 2: 146-157.
32. Fossa AA. Assessing QT prolongation in conscious dogs: Validation of a beat-to-beat method. Pharmacol Ther, 2008; 119: 133-140.
33. Fossa AA. The impact of varying autonomic states on the dynamic beat-to-beat QT-RR and QT-TQ interval relationships. Br J Pharmacol, 2008; 154: 1508-1515.
34. Fossa AA, Depasquale MJ, Raunig DL, Avery MJ, Leishman DJ. The relationship of clinical QT prolongation to outcome in the conscious dog using a beat-to-beat QT-RR interval assessment. J Pharmacol Exp Ther, 2002; 202: 828-833.
35. Franz MR, Swerdlow CD, Liem LB, Schaefer J. Cycle length dependence of human action potential duration in vivo: effects of single extrastimuli, sudden sustained rate acceleration and deceleration and different steady-state frequencies. J Clin Invest, 1988; 82: 972-979.
36. Davidowski TA, Wolf S. The QT interval during reflex cardiovascular adaptation. Circulation, 1984; 69: 22-25.
37. Pueyo E, Smetana P, Caminal P, Bayes de Luna A, Malik M, Laguna P. Characterization of QT interval adaptation to RR interval changes and its use as a risk-stratifier of arrhythmic mortality in amiodarone-treated survivors of acute myocardial infarction. IEEE Trans Biomed Eng, 2004; 51: 1511-1520.
38. Krahn AD, Klein GJ, Yee R. Hysteresis of the RT interval with exercise: A new marker for the long QT syndrome? Circulation, 1997; 96: 1551-1561.
39. Walker BD, Krahn AD, Klein GJ, Skanes, Yee R. Burst bicycle exercise facilitates diagnosis of latent long QT-syndrome. Am Heart J, 2005; 150: 1059-1063.
40. Batchvarov VN, Ghuran A, Smetana P et al. QT-RR relationship in healthy subjects exhibits substantial intersubject variability and high intrasubject stability. Am J Physiol Heart Circ Physiol, 2002; 282: H2356-H2363.
41. Locati EH, Maison-Blanche P, Dejode P, Cauchemez B, Coumel P. Spontaneous sequences of onset of torsade de pointes in patients with acquired prolonged repolarization: Quantitative analysis of Holter recording. J Am Coll Cardiol, 1995; 25: 1564-1575.
42. Schwartz PJ, Priori SG, Spazzolini C et al. Genotype-phenotype correlation in the long-QT syndrome gene-specific triggers for life-threatening arrhythmias. Circulation, 2001; 103: 89-95.
43. La Rovere MT, Bigger JT Jr, Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. Lancet, 1998; 351: 478-484.